TWI907424B - 含甲硫鎓化合物於治療或減輕低氧血症之用途 - Google Patents

含甲硫鎓化合物於治療或減輕低氧血症之用途

Info

Publication number
TWI907424B
TWI907424B TW110116178A TW110116178A TWI907424B TW I907424 B TWI907424 B TW I907424B TW 110116178 A TW110116178 A TW 110116178A TW 110116178 A TW110116178 A TW 110116178A TW I907424 B TWI907424 B TW I907424B
Authority
TW
Taiwan
Prior art keywords
acid
subject
hypoxia
disease
total daily
Prior art date
Application number
TW110116178A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200149A (zh
Inventor
克勞德米歇爾 威斯奇克
穆罕默德 亞拉斯圖
麥可菲力普 瑪薩納茲
Original Assignee
新加坡商威斯塔實驗室公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2006659.3A external-priority patent/GB202006659D0/en
Priority claimed from GBGB2016957.9A external-priority patent/GB202016957D0/en
Application filed by 新加坡商威斯塔實驗室公司 filed Critical 新加坡商威斯塔實驗室公司
Publication of TW202200149A publication Critical patent/TW202200149A/zh
Application granted granted Critical
Publication of TWI907424B publication Critical patent/TWI907424B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110116178A 2020-05-05 2021-05-05 含甲硫鎓化合物於治療或減輕低氧血症之用途 TWI907424B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB2006659.3 2020-05-05
GBGB2006659.3A GB202006659D0 (en) 2020-05-05 2020-05-05 Therapeutic treatments
GB2016957.9 2020-10-26
GBGB2016957.9A GB202016957D0 (en) 2020-10-26 2020-10-26 Beneficial treatment

Publications (2)

Publication Number Publication Date
TW202200149A TW202200149A (zh) 2022-01-01
TWI907424B true TWI907424B (zh) 2025-12-11

Family

ID=75887990

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110116178A TWI907424B (zh) 2020-05-05 2021-05-05 含甲硫鎓化合物於治療或減輕低氧血症之用途

Country Status (12)

Country Link
US (1) US20230158040A1 (https=)
EP (1) EP4146225B1 (https=)
JP (1) JP2023524146A (https=)
KR (1) KR20230012515A (https=)
CN (1) CN115916211A (https=)
AU (1) AU2021268465A1 (https=)
CA (1) CA3181388A1 (https=)
ES (1) ES2992641T3 (https=)
MX (1) MX2022013884A (https=)
PL (1) PL4146225T3 (https=)
TW (1) TWI907424B (https=)
WO (1) WO2021224146A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202204185D0 (en) 2022-03-24 2022-05-11 Wista Lab Ltd Oral treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020751A1 (en) * 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
US20060264423A1 (en) 2005-05-20 2006-11-23 Bioenvision, Inc. Methylene Blue Therapy of Viral Disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
EP3982974A4 (en) * 2019-06-12 2023-06-21 Achal Narendrakumar Agrawal NOVEL IMPROVED PROCESS FOR THE SYNTHESIS OF DIAMINOPHENOTHIAZINE COMPOUNDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020020751A1 (en) * 2018-07-26 2020-01-30 Wista Laboratories Ltd. Optimised dosage of diaminophenothiazines in populations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Hamidi Alamdari D, et al., The Application of a Reduced Dye Used in Orthopedics as a Novel Treatment against Coronavirus (COVID-19): A Suggested Therapeutic Protocol, Arch Bone Jt Surg., (Suppl1):291-294, 2020/04/08. *

Also Published As

Publication number Publication date
EP4146225B1 (en) 2024-10-09
TW202200149A (zh) 2022-01-01
BR112022022322A2 (pt) 2022-12-13
ES2992641T3 (en) 2024-12-16
CN115916211A (zh) 2023-04-04
MX2022013884A (es) 2022-11-30
JP2023524146A (ja) 2023-06-08
WO2021224146A1 (en) 2021-11-11
US20230158040A1 (en) 2023-05-25
PL4146225T3 (pl) 2025-03-10
AU2021268465A1 (en) 2022-12-08
EP4146225C0 (en) 2024-10-09
EP4146225A1 (en) 2023-03-15
KR20230012515A (ko) 2023-01-26
CA3181388A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
Abbruzzi et al. Pediatric toxicologic concerns
TWI907424B (zh) 含甲硫鎓化合物於治療或減輕低氧血症之用途
CN104519881A (zh) 使用no(一氧化氮)供体诱导动脉生成
TW202200150A (zh) 治療處理
HK40088921B (en) Methylthioninium compounds for use in the treatment of hypoxemia
HK40088921A (en) Methylthioninium compounds for use in the treatment of hypoxemia
BR112022022322B1 (pt) Uso de compostos de metiltionínio para preparação de medicamento oral para tratamento de hipoxemia
Ichinose et al. Inhaled nitric oxide—current practice and future potential uses and development
JP2022033333A (ja) 心血管代謝疾患の治療剤または予防剤
US20250222005A1 (en) Methylene blue containing compounds for the treatment of methaemoglobinaemia
TW202200151A (zh) 治療處理
Iliev et al. Acute poisoning with dapsone and olanzapine: severe methemoglobinemia and coma with a favourable outcome
Mollamohammadi et al. Severe Neurological Complications Caused by Lidocaine Ingestion in an Infant: A Case Report
JP2010528057A (ja) ピリドキサール５’−リン酸による遅発性ジスキネジーの治療
Ramsakal et al. A potentially fatal effect of topical anesthesia
Omar Inorganic Nitrite and Conduit Artery Function